首页 | 本学科首页   官方微博 | 高级检索  
     

肝动脉插管化疗栓塞治疗中晚期肝癌及其并发症的防治
引用本文:张继广,许崇恩,孙启龙. 肝动脉插管化疗栓塞治疗中晚期肝癌及其并发症的防治[J]. 中华肿瘤防治杂志, 1996, 0(3)
作者姓名:张继广  许崇恩  孙启龙
作者单位:山东医科大学附属医院
摘    要:
我们运用导管法治疗65例中晚期肝癌,巨块型占61.3%,结节型占26.1%,弥漫型占21.6%,患者肿瘤直径约3cm~18cm不等。随访6-33个月,多数患者治疗后肿瘤缩小,单纯灌注化疗组12个月生存率为6.6%,化疗+碘油+明胶海绵生存率最高为37.5%,最长的1例,生存30个月。影响疗效的因素有:(1)肿瘤分期,(2)门静脉癌栓,(3)肝动脉治疗方法。并探讨治疗后并发症的产生原因和预防措施。

关 键 词:肝癌  并发症  栓塞化疗  肝动脉插管

Hepatic Arterial Infusion Chemotherapy and Embolization in the Treatment of Hepatocellular Carcinoma and Prevention of the Complications after Treatment
Zhang Jiguang,XuChong'en,Sun Qilong. Hepatic Arterial Infusion Chemotherapy and Embolization in the Treatment of Hepatocellular Carcinoma and Prevention of the Complications after Treatment[J]. Chinese Journal of Cancer Prevention and Treatment, 1996, 0(3)
Authors:Zhang Jiguang  XuChong'en  Sun Qilong
Abstract:
patients with moderate and advanced stage of hepatocellular carcinoma were treated with hepatic arterial infusion chemotherapy and embolization.Among them,61.3% was of massive type,26.1% of nodular type and 13.8% of diffusd infiltrating type.the size of tumors were 3cm to 18cm.Mostofthe tumors decreased in size after the treatment.In 65 patients follow ups were six to thirty three months.The one year survival rate was 6.6%in the hepatic arterial infusion group and 37.5^ in the hepatic arterial infusion hepatic arterial embolization (Iodizedoil Gelfoam)group.The longest survival period was 30 months after initial hepatic arterial infusion and emboliization.Factors influencing theraputic effect were:(1)stage of tumor,(2)tumr or thrombus in the portal vein,(3)methods of hepatic infusion and hepatic arterial embolization.The cause of complication after the treament and the way of prevention were discussed in detail.
Keywords:HCC (Hepatocellular carcinoma) Chemotherapy and embolization Hepatic arterial catheterization Complication.
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号